# Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer

> **NCT00909558** · PHASE1 · SUSPENDED · sponsor: **Envita Medical Center, Inc.** · enrollment: 24 (estimated)

## Conditions studied

- Breast Cancer
- Glioma
- Hepatocellular Cancer
- Squamous Cell Lung Cancer
- Pancreatic Cancer
- Colon Cancer
- Prostate Cancer

## Interventions

- **BIOLOGICAL:** Autologous Natural Killer / Natural Killer T Cell Immunotherapy

## Key facts

- **NCT ID:** NCT00909558
- **Lead sponsor:** Envita Medical Center, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** SUSPENDED
- **Start date:** 2009-05
- **Primary completion:** 2010-06
- **Final completion:** —
- **Target enrollment:** 24 (ESTIMATED)
- **Last updated:** 2010-02-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00909558

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00909558, "Safety and Effectiveness Study of Autologous Natural Killer and Natural Killer T Cells on Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT00909558. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*